n/a
Article Publish Status: FREE
Abstract Title:

Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma.

Abstract Source:

Ital J Pediatr. 2017 Mar 7 ;43(1):25. Epub 2017 Mar 7. PMID: 28270216

Abstract Author(s):

Michele Miraglia Del Giudice, Cristiana Indolfi, Michele Capasso, Nunzia Maiello, Fabio Decimo, Giorgio Ciprandi

Article Affiliation:

Michele Miraglia Del Giudice

Abstract:

BACKGROUND: Allergic rhinitis (AR) and allergic asthma are caused by an IgE-mediated inflammatory reaction. Probiotics may exert anti-inflammatory and immune-modulatory activity. Thus, this study aimed at investigating whether a Bifidobacteria mixture could be able to relieve nasal symptoms, and affect quality of life (QoL) in children with AR and intermittent asthma due to Parietaria allergy.

MATERIALS AND METHODS: The present study was conducted as placebo-controlled, double-blinded, and randomized. Globally, 40 children (18 males; mean age 9 ± 2.2 years) were enrolled. They were treated with probiotics or placebo: 1 sachet/day for 4 weeks. AR symptoms, and QoL were assessed at baseline and after treatment. Use of rescue medications, such as cetirizine syrup and salbutamol spray, was also permitted and recorded.

RESULTS: Children treated with probiotic mixture achieved a significant improvement of symptoms (p < 0.005), and QoL ((p < 0.001). Placebo group had worsening of symptoms (p < 0.005) and QoL (p < 0.001). The use of rescue medications was overlapping in the two groups. The intergroup analysis showed that probiotic mixture was significantly superior than placebo for all parameters.

CONCLUSIONS: The current study demonstrated that a Bifidobacteria mixture was able of significantly improving AR symptoms and QoL in children with pollen-induced AR and intermittent asthma.

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID NCT02807064 .

Study Type : Human Study

Print Options


Key Research Topics